Last quarter (Q3 2024), KalVista Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, KalVista Pharmaceuticals's net income was $-29.03M. See KalVista Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Apr 23	Apr 22	Apr 21	Apr 20	Apr 19
Total Revenue	-	-	-	$ 0.00	$ 12.69M	$ 16.13M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 282.00M	$ 110.87M	$ 96.61M	$ 57.92M	$ 53.22M	$ 45.95M
Operating Income	$ -123.72M	$ -110.87M	$ -96.61M	$ -57.92M	$ -40.53M	$ -29.82M
Net Non Operating Interest Income Expense	$ 3.19M	$ 2.23M	$ 1.09M	$ 903.00K	$ 1.83M	$ 1.40M
Other Income Expense	$ -11.62M	$ -15.64M	$ -14.72M	$ 10.78M	$ 9.46M	$ 7.73M
Pretax Income	$ -108.30M	$ -92.91M	$ -82.34M	$ -46.24M	$ -29.24M	$ -20.69M
Tax Provision	-	-	-	$ 0.00	$ -124.00K	$ 124.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -108.30M	$ -92.91M	$ -82.34M	$ -46.24M	$ -29.12M	$ -20.82M
Basic EPS	$ -3.12	$ -3.33	$ -3.36	$ -2.42	$ -1.64	$ -1.38
Diluted EPS	$ -3.12	$ -3.33	$ -3.36	$ -2.42	$ -1.64	$ -1.38
Basic Average Shares	$ 131.59M	$ 27.89M	$ 24.47M	$ 19.09M	$ 17.75M	$ 15.08M
Diluted Average Shares	$ 131.59M	$ 27.89M	$ 24.47M	$ 19.09M	$ 17.75M	$ 15.08M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 282.00M	$ 110.87M	$ 96.61M	$ 57.92M	$ 53.22M	$ 45.95M
Net Income From Continuing And Discontinued Operation	$ -108.30M	$ -92.91M	$ -82.34M	$ -46.24M	$ -29.12M	$ -20.82M
Normalized Income	$ -81.18M	-	-	$ -47.09M	$ -28.75M	$ -20.86M
Interest Expense	-	-	-	-	-	-
EBIT	$ -108.30M	$ -92.91M	$ -82.34M	$ -57.92M	$ -40.53M	$ -29.82M
EBITDA	$ -107.35M	$ -91.22M	$ -79.17M	$ -57.39M	$ -40.02M	$ -29.44M

Currency in USD

KalVista Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing